RxDoctor Payments DataLook up a doctor →

Clifford Stermer, MD

Rheumatology · Palm Beach Gardens, FLNPI 1730529918

Payments from drug & device makers

$473,186in general payments, 2019–2025

Across 957 payments — averaging $494.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$124K
  • Eli Lilly$109K
  • Lilly USA, LLC$74K
  • Sanofi$61K
  • UCB, Inc.$46K
  • Sanofi US Services Inc.$25K
  • plus $34K from 28 others
$33,930in research payments, 2019–2025

Across 3 payments — averaging $11,310 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$34K

What the payments were for

  • Consulting fees$14,8908%
  • Speaking & faculty fees$149,78776%
  • Grants$2400%
  • Travel & lodging$10,1955%
  • Food & beverage$20,30210%
  • Education$6340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$473,186 in reported general payments places this provider in the 85th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$1,013,268
Medicare patients
401
Services billed
57,459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KevzaraSarilumab50$243,280
RinvoqUpadacitinib31$210,276
Xeljanz XrTofacitinib Citrate28$163,697
Humira(Cf) PenAdalimumab22$150,338
Enbrel MiniEtanercept19$134,267
Orencia ClickjectAbatacept21$133,039
Enbrel SureclickEtanercept18$126,780
ForteoTeriparatide12$51,221
Hydroxychloroquine Sulfate318$17,150
MethotrexateMethotrexate Sodium200$6,442
Colchicine64$3,685
Prednisone312$3,617
Mycophenolate Mofetil16$2,118
Methylprednisolone90$1,380
Allopurinol123$1,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiKevzara$61,275$243,28050 claims
AbbVieRinvoq$124,145$210,27631 claims
Lilly USA, LLCForteo$73,742$51,22112 claims
Scilex Pharmaceuticals Inc.Colchicine$83$3,68564 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Palm Beach Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →